12/27/2011
Battle Over Generic Drugs Could Pressure Sales at Rite Aid
Walmart's entry into the generic drug market could impact Rite Aid's drug sales, according to a Zacks analyst blog. Zacks has a neutral rating on Rite Aid, citing competitive pressures and the company's 162 percent debt-to-capitalization ratio in fiscal 2011, stemming from the Brooks Eckerd acquisition. Rite Aid, which is the third largest drug store chain in the United States with 4,714 stores in 31 states, expects to post a loss for fiscal 2012, Zacks reported.